Defects in G1-S cell cycle control in head and neck cancer: A review

Head and Neck

Volumn 24, Issue 7, 2002, Pages 694-704

  Michalides, Rob J A M ^a   Van De Brekel, Michiel ^a   Balm, Fons ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cell cycle control; Cyclins; Head and neck cancer

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; CELL AGING; CELL CYCLE G1 PHASE; CELL INTERACTION; CELL PROLIFERATION; DRUG TARGETING; GENE FUNCTION; GENETIC ASSOCIATION; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TUMOR ESCAPE;

ANEUPLOIDY; APOPTOSIS; CELL DIFFERENTIATION; CYCLINS; DNA DAMAGE; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; KI-67 ANTIGEN; MITOSIS; PHOSPHORYLATION; S PHASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036301225     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10109     Document Type: Review

References (93)

1. The hallmarks of cancer
2. Temporal and spatial control of cyclin B1 destruction in metaphase
3. Regulation of the APC and the exit from mitosis
4. Re-staging mitosis: A contemporary view of mitotic progression
5. G1 events and regulation of proliferation
6. The ins and outs of signaling
7. Key effectors of signal transduction and G1 progression
8. Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications
9. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
10. NF-ΚB controls cell growth and differentiation through transcriptional regulation of cyclin D1
11. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site
12. Regulation of the cyclin E gene by transcription factor E2F1
13. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity
14. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex
15. 1 cyclin-dependent kinases in the mammalian cell cycle
16. Cyclin-dependent kinases: Engines, clocks and microprocessors
17. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
18. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E
19. CDK inhibitors: Positive and negative regulators of G1-phase progression
20. New functional activities for the p21 family of CDK inhibitors
21. Estrogen dependent cyclin E-cdk2 activation through p21 redistribution
22. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation
23. INK4b
24. Cell cycle regulators: Mechanisms and their role in aetiology, prognosis, and treatment of cancer
25. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression
26. Cyclin D1-CDK4 complex, a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas
27. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and the neck
28. Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma
29. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
30. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma
31. Reconstruction of cyclin D1-associated kinase activity drives terminally differentiated cells into the cell cycle
32. Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas
33. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit
34. Anoikis mechanisms
35. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
36. Transcriptional repression by Rb-E2f and regulation of anchorage-independent survival
37. 1phase of the cell cycle
38. Role of the F-Box protein Skp2 in adhesion-dependent cell cycle progression
39. Cell-to-cell contact and extracellular matrix web alert
40. Regulation of cadherin adhesive activity
41. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer
42. A causal role for E-cadherin in the transition from adenoma to carcinoma
43. Hyperproliferation and defects in epithelial polarity upon conditional ablation of α-catenin in skin
44. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas
45. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value
46. Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas
47. The DNA damage response: Putting checkpoints in perspective
48. Cell-cycle checkpoint kinases: Checking in on the cell cycle
49. The ATM-Chk2-Cdc25A checkpoint pathways guards against radioresistant DNA synthesis
50. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1
51. Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216
52. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
53. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage
54. Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line
55. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation
56. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma
57. Proliferation, cell cycle and apoptosis in cancer
58. Apaf1 is a transcriptional target for E2F and p53
59. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
60. The Pezcoller lecture: Cancer cell cycles revisited
61. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis
62. The presence of p53 protein in relation to Ki-67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa
63. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma
64. Cyclin D1 and p53 overexpression predicts multiple primary malignant neoplasms of the hypopharynx and esophagus
65. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer
66. p53 Expression: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
67. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma
68. Chromosome instability as an indicator of malignant progression in laryngeal mucosa
69. Mutations of mitotic checkpoint genes in human cancer
70. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression
71. Centrosome hyperamplification in human cancer: Chromosome instability induced by p53 mutation and/or Mdm2 overexpression
72. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A
73. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication
74. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression
75. Antisense Inhibition of cyclin D1 in human head and neck squamous cell carcinoma
76. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas
77. Chemoprevention of head and neck cancer
78. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway
79. Small molecule modulators of cyclin-dependent kinases for cancer therapy
80. Preclinical and clinical development of cyclin-dependent kinase modulators
81. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
82. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
83. Pharmacological rescue of mutant p52 conformation and function
84. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
85. Activation of p53 in cervical carcinoma cells by small molecules
86. ONYX-015 selectivity and the p14ARF pathway
87. A controlled trial of intratumoral ONYX-015, a selectively- replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
88. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
89. Signaling pathways in apoptosis as potential targets for cancer therapy
90. The Ki-67 protein: From the known and the unknown
91. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus
92. Prognostic value of p53, proliferation cell nuclear antigen and Ki-67 expression in undifferentiated nasopharyngeal carcinomas
93. Cell cycle proteins and the development of oral squamous cell carcinoma